Dermira Inc. (DERM) to Post FY2016 Earnings of ($3.48) Per Share, Leerink Swann Forecasts
Dermira Inc. (NASDAQ:DERM) – Analysts at Leerink Swann cut their FY2016 earnings per share estimates for Dermira in a research note issued on Tuesday. Leerink Swann analyst S. Fernandez now forecasts that the firm will post earnings of ($3.48) per share for the year, down from their prior estimate of ($3.38). Leerink Swann has a “Buy” rating on the stock. Leerink Swann also issued estimates for Dermira’s Q4 2016 earnings at ($0.93) EPS, FY2017 earnings at ($2.80) EPS and FY2018 earnings at ($2.48) EPS.
Dermira (NASDAQ:DERM) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, meeting the consensus estimate of ($0.72).
DERM has been the subject of several other research reports. Needham & Company LLC reaffirmed a “positive” rating and issued a $46.00 target price on shares of Dermira in a research report on Monday, October 3rd. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.00.
Dermira (NASDAQ:DERM) opened at 35.15 on Thursday. Dermira has a 52 week low of $17.42 and a 52 week high of $36.34. The firm has a 50 day moving average price of $33.01 and a 200 day moving average price of $31.21. The stock’s market capitalization is $1.24 billion.
A number of hedge funds have recently made changes to their positions in DERM. TimesSquare Capital Management LLC boosted its stake in shares of Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock valued at $72,877,000 after buying an additional 1,101,645 shares during the last quarter. FMR LLC boosted its stake in shares of Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock valued at $118,847,000 after buying an additional 921,800 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock valued at $73,539,000 after buying an additional 860,597 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in shares of Dermira during the second quarter valued at about $10,678,000. Finally, Vanguard Group Inc. boosted its stake in shares of Dermira by 47.9% in the second quarter. Vanguard Group Inc. now owns 941,164 shares of the biopharmaceutical company’s stock valued at $27,529,000 after buying an additional 304,750 shares during the last quarter. Hedge funds and other institutional investors own 82.50% of the company’s stock.
In other Dermira news, VP Christopher M. Griffith sold 1,303 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $31.75, for a total transaction of $41,370.25. Following the sale, the vice president now owns 44,941 shares in the company, valued at $1,426,876.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew Guggenhime sold 4,100 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $35.02, for a total value of $143,582.00. Following the sale, the chief financial officer now owns 9,216 shares in the company, valued at approximately $322,744.32. The disclosure for this sale can be found here. 17.30% of the stock is owned by corporate insiders.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.